HC Wainwright & Co. Maintains Buy on Blueprint Medicines, Raises Price Target to $135
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein maintains a Buy rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $125 to $135.
May 03, 2024 | 8:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Blueprint Medicines' price target was raised from $125 to $135 by HC Wainwright & Co., maintaining a Buy rating.
The increase in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the stock, suggesting potential upside. This could lead to increased investor confidence and a short-term rise in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100